A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 among U.S. adults without diabetes.
The research, published April 1 in the Annals of Internal Medicine, showed the number of non-diabetic adults using these drugs — which are also prescribed for weight loss — more than tripled from 2018 to 2022, rising from 0.1% to 0.4% of the U.S. population, or an estimated 854,000 people.
Despite the high cost, averaging $1,540 per prescription, patients paid around $35 out of pocket per fill, according to the study.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.